Guardant Health’s CEO Helmy Eltoukhy expects the launch of the company’s new liquid biopsy test, indicated for detecting early-stage colorectal cancer, will be a “big game changer.”
The new liquid biopsy test, Guardant Reveal, is a plasma-only circulating tumor DNA (ctDNA) test indicated for detecting residual and recurrent disease from a whole blood draw. The minimal residue...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?